SK Chemical said Monday that it recorded consolidated revenue of 740.8 billion won and an operating profit of 33.6 billion won for the third quarter this year. Revenue increased by 21.5% and operating profit rose by 115.6% compared to the same period last year. On a standalone basis, revenue was 402.1 billion won and operating profit was 16.4 billion won.
The company explained that despite deteriorating business conditions in the chemical industry due to rising raw material prices and falling exchange rates, it maintained its profitability trend as the earnings of consolidated subsidiaries such as SK Bioscience improved. The reflection of results from the SK Multi-Utility cogeneration plant, which began commercial operation in November last year, also contributed to the revenue increase.
By business segment, revenue in the copolyester and monomer division reached 237.5 billion won, a 13.9% increase over the same period last year. This was due to expanded sales of high-value-added products such as cosmetic containers.
The pharmaceutical business achieved revenue of 139.2 billion won and an operating profit of 9.7 billion won, driven by strong sales of key products including Joins and Gineksin. These figures represent increases of 0.9% and 2.5%, respectively, compared to the same period last year.
SK Chemical plans to enhance the cost competitiveness of its core businesses, such as copolyesters, and expand sales of high-value-added products. It will also seek new growth opportunities in the bio and cogeneration sectors.
An SK Chemical official said, "Despite the challenging environment across the chemical industry, we continued to post consolidated profits based on our diversified business structure," adding, "We will enhance the cost competitiveness of our core businesses and expand sales of high-value-added products."
in INDUSTRY
